Literature DB >> 22939725

A nomogram for predicting lymph node metastasis of presumed stage I and II endometrial cancer.

Sofiane Bendifallah1, Anne Sophie Genin, Iptissem Naoura, Nathalie Chabbert Buffet, Francoise Clavel Chapelon, Bassam Haddad, Dominique Luton, Emile Darai, Roman Rouzier, Martin Koskas.   

Abstract

OBJECTIVE: Our objective was to develop a nomogram based on pathological hysterectomy characteristics to provide a more individualized and accurate estimation of lymph node metastasis in endometrial cancer. STUDY
DESIGN: Data from the Surveillance, Epidemiology, and End Results database for 18,294 patients who underwent hysterectomy and lymphadenectomy were analyzed. A multivariate logistic regression analysis of selected prognostic features was performed, and a nomogram to predict lymph node metastasis was constructed. A cohort of 434 patients was used for the external validation.
RESULTS: The nomogram showed good discrimination with an area under the receiver operating characteristic curve of 0.80 (95% confidence interval, 0.79-0.81) in the training set and 0.79 (95% confidence interval, 0.78-0.80) in the validation set. The nomogram was well calibrated.
CONCLUSION: We developed a nomogram based on 5 clinical and pathological characteristics to predict lymph node metastasis with a high concordance probability.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22939725     DOI: 10.1016/j.ajog.2012.06.080

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  11 in total

1.  Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia.

Authors:  Anthony B Costales; Kathleen M Schmeler; Russell Broaddus; Pamela T Soliman; Shannon N Westin; Pedro T Ramirez; Michael Frumovitz
Journal:  Gynecol Oncol       Date:  2014-10-12       Impact factor: 5.482

2.  Validation of REM score to predict endometrial cancer in patients with ultrasound endometrial abnormalities: results of a new independent dataset.

Authors:  Francesco Plotti; Stella Capriglione; Corrado Terranova; Roberto Montera; Giuseppe Scaletta; Salvatore Lopez; Daniela Luvero; Antonelli Gianina; Alessia Aloisi; Pierluigi Benedetti Panici; Roberto Angioli
Journal:  Med Oncol       Date:  2017-04-07       Impact factor: 3.064

Review 3.  American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review.

Authors:  Matthew M Harkenrider; Alec M Block; Kaled M Alektiar; David K Gaffney; Ellen Jones; Ann Klopp; Akila N Viswanathan; William Small
Journal:  Brachytherapy       Date:  2016-05-31       Impact factor: 2.362

4.  Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial.

Authors:  Ashley S Felix; D Scott McMeekin; David Mutch; Joan L Walker; William T Creasman; David E Cohn; Shamshad Ali; Richard G Moore; Levi S Downs; Olga B Ioffe; Kay J Park; Mark E Sherman; Louise A Brinton
Journal:  Gynecol Oncol       Date:  2015-09-01       Impact factor: 5.482

5.  Just how accurate are the major risk stratification systems for early-stage endometrial cancer?

Authors:  S Bendifallah; G Canlorbe; P Collinet; E Arsène; F Huguet; C Coutant; D Hudry; O Graesslin; E Raimond; C Touboul; E Daraï; M Ballester
Journal:  Br J Cancer       Date:  2015-02-12       Impact factor: 7.640

6.  A novel model to estimate lymph node metastasis in endometrial cancer patients.

Authors:  Cristina Anton; Alexandre Silva E Silva; Edmund Chada Baracat; Nasuh Utku Dogan; Christhardt Köhler; Jesus Paula Carvalho; Giovanni Mastrantonio di Favero
Journal:  Clinics (Sao Paulo)       Date:  2017-01-01       Impact factor: 2.365

7.  An external validation study of nomograms designed to predict isolated loco-regional and distant endometrial cancer recurrences: how applicable are they?

Authors:  S Bendifallah; G Canlorbe; E Raimond; L Bazire; F Huguet; O Graesslin; R Rouzier; E Darai; M Ballester
Journal:  Br J Cancer       Date:  2013-08-29       Impact factor: 7.640

8.  Accuracy of a nomogram for prediction of lymph-node metastasis detected with conventional histopathology and ultrastaging in endometrial cancer.

Authors:  M Koskas; E Chereau; M Ballester; G Dubernard; F Lécuru; D Heitz; P Mathevet; H Marret; D Querleu; F Golfier; E Leblanc; D Luton; R Rouzier; E Daraï
Journal:  Br J Cancer       Date:  2013-03-12       Impact factor: 7.640

9.  External multicentre validation of a nomogram predicting the risk of relapse in patients with borderline ovarian tumours.

Authors:  S Bendifallah; C Uzan; R Fauvet; P Morice; E Darai
Journal:  Br J Cancer       Date:  2013-10-29       Impact factor: 7.640

10.  Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1.

Authors:  Yuan Yang; Jingyi Zhou; Xiaoping Li; Lijun Zhao; Yuan Cheng; Yanying Lin; Jiaqi Wang; Lihui Wei; Yafeng Dong; Jianliu Wang
Journal:  Oncotarget       Date:  2017-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.